# EDGAR Filing Document

**Accession Number:** 0001648257
**File Stem:** 0001104659-26-027988
**Filing Date:** 2026-3
**Character Count:** 7749
**Document Hash:** 60168c1b9e4df3dc648ffbb90358e298
**Contains OCR:** False
**Source Format:** 

## Filing Content

## Filing Summary
**0001104659-26-027988.hdr.sgml**: 20260316

**ACCESSION NUMBER**: 0001104659-26-027988

**CONFORMED SUBMISSION TYPE**: 3

**PUBLIC DOCUMENT COUNT**: 1

**CONFORMED PERIOD OF REPORT**: 20260316

**FILED AS OF DATE**: 20260316

**DATE AS OF CHANGE**: 20260316

**REPORTING-OWNER**: 

**OWNER DATA:**
- **COMPANY CONFORMED NAME:** Su Wei-guo
- **CENTRAL INDEX KEY:** 0002113925

**ORGANIZATION NAME:**

**FILING VALUES:**
- **FORM TYPE:** 3
- **SEC ACT:** 1934 Act
- **SEC FILE NUMBER:** 001-37710
- **FILM NUMBER:** 26754482

**MAIL ADDRESS:**
- **ADDRESS IS A NON US LOCATION:** YES
- **STREET 1:** C/O 48TH FLOOR, CHEUNG KONG CENTER
- **STREET 2:** 2 QUEEN'S ROAD CENTRAL
- **CITY:** HONG KONG
- **PROVINCE COUNTRY:** F4
- **ZIP:** 00000
**ISSUER**: 

**COMPANY DATA:**
- **COMPANY CONFORMED NAME:** HUTCHMED (China) Ltd
- **CENTRAL INDEX KEY:** 0001648257
- **STANDARD INDUSTRIAL CLASSIFICATION:** PHARMACEUTICAL PREPARATIONS [2834]
- **ORGANIZATION NAME:** 03 Life Sciences
- **EIN:** 000000000
- **STATE OF INCORPORATION:** E9

**BUSINESS ADDRESS:**
- **ADDRESS IS A NON US LOCATION:** YES
- **STREET 1:** 48TH FLOOR, CHEUNG KONG CENTER
- **STREET 2:** 2 QUEEN'S ROAD CENTRAL
- **CITY:** HONG KONG
- **PROVINCE COUNTRY:** K3
- **BUSINESS PHONE:** 852-2121-3888

**MAIL ADDRESS:**
- **ADDRESS IS A NON US LOCATION:** YES
- **STREET 1:** 48TH FLOOR, CHEUNG KONG CENTER
- **STREET 2:** 2 QUEEN'S ROAD CENTRAL
- **CITY:** HONG KONG
- **PROVINCE COUNTRY:** K3

**FORMER COMPANY:**
- **FORMER CONFORMED NAME:** Hutchison China MediTech Ltd
- **DATE OF NAME CHANGE:** 20150716

### UNITED STATES SECURITIES AND EXCHANGE COMMISSION
**Washington, D.C. 20549**

## FORM 3

### INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF SECURITIES

[ ] Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

---

| | | |
|:---|:---|:---|
| **1. Name and Address of Reporting Person**<sup>*</sup><br>Su Wei-guo<br><sub>(Last) (First) (Middle)</sub><br>C/O 48TH FLOOR, CHEUNG KONG CENTER, 2<br>QUEEN'S ROAD CENTRAL<br><sub>(Street)</sub><br>HONG KONG, K3 00000<br><sub>(City) (State) (Zip)</sub> | **3. Issuer Name and Ticker or Trading Symbol**<br>HUTCHMED (China) Ltd [ HCM ] | **5. If Amendment, Date of Original Filed (Month/Day/Year)**<br>  |
| **2. Date of Event Requiring Statement (Month/Day/Year)**<br>2026-03-16 | **4. Relationship of Reporting Person(s) to Issuer**<br>(Check all applicable)<br>[X] Director   [ ] 10% Owner<br>[X] Officer (give title below)   [ ] Other (specify below)<br>_CEO and CSO_ | **6. Individual or Joint/Group Filing (Check Applicable Line)**<br>[X] Form filed by One Reporting Person<br>[ ] Form filed by More than One Reporting Person |

---

## Table I - Non-Derivative Securities Beneficially Owned

---

|  |  |  |  |
| --- | --- | --- | --- |
| 1. Title of Security | 2. Amount of Securities Beneficially Owned | 3. Ownership Form | 4. Nature of Indirect Beneficial Ownership |
| ordinary shares | 3563905 | D |  |
| American depositary shares<sup>(1)</sup> | 237063 | D |  |

---

## Table II - Derivative Securities Beneficially Owned

---

|  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- |
| 1. Title of Derivative Security | 2. Date Exercisable and Expiration Date (Month/Day/Year) | 2. Date Exercisable and Expiration Date (Month/Day/Year) | 3. Title and Amount of Underlying Securities | 3. Title and Amount of Underlying Securities | 4. Conversion or Exercise Price | 5. Ownership Form | 6. Nature of Indirect Beneficial Ownership |
| 1. Title of Derivative Security | Date Exercisable | Expiration Date | Title | Amount or Number of Shares | 4. Conversion or Exercise Price | 5. Ownership Form | 6. Nature of Indirect Beneficial Ownership |
| Share option (right to buy)<sup>(2)</sup> | 2017-03-27 | 2027-03-26 | ordinary shares | 1000000 | <sup>(3)</sup> | D |  |
| Share option (right to buy)<sup>(2)</sup> | 2018-03-19 | 2028-03-18 | ordinary shares | 1000000 | <sup>(4)</sup> | D |  |
| Share option (right to buy)<sup>(2)</sup> | 2020-04-28 | 2030-04-27 | American depositary shares | 157940 | 22.090<sup>(5)</sup> | D |  |
| Share option (right to buy)<sup>(2)</sup> | 2020-12-14 | 2030-12-13 | American depositary shares | 3792 | 29.000<sup>(5)</sup> | D |  |
| Share option (right to buy)<sup>(2)</sup> | 2021-03-26 | 2031-03-25 | American depositary shares | 56480 | 27.940<sup>(5)</sup> | D |  |
| Share option (right to buy)<sup>(2)</sup> | 2021-12-14 | 2031-12-13 | American depositary shares | 4986 | 35.210<sup>(5)</sup> | D |  |
| Share option (right to buy)<sup>(6)</sup> | 2024-08-05 | 2034-08-04 | ordinary shares | 1405767 | <sup>(7)</sup> | D |  |
| Share option (right to buy)<sup>(6)</sup> | 2025-06-09 | 2035-06-08 | ordinary shares | 1493435 | <sup>(8)</sup> | D |  |
| Long Term Incentive Plan awards granted on 03/13/2024 | <sup>(9)</sup> | <sup>(9)</sup> | ordinary shares | 39862 | <sup>(9)</sup> | I | Held by Long Term Incentive Plan trustee |
| Long Term Incentive Plan awards granted on 08/05/2024 | <sup>(10)</sup> | <sup>(10)</sup> | ordinary shares | 169977 | <sup>(10)</sup> | I | Held by Long Term Incentive Plan trustee |

---

### Footnotes:

(1) Each American depositary share represents 5 ordinary shares.

(2) The share options granted are exercisable subject to, amongst other relevant vesting criteria, the vesting schedule of 25% on each of the first, second, third and fourth anniversaries of the date of grant of share options.

(3) The exercise price for the share option is GBP3.105 per ordinary share.

(4) The exercise price for the share option is GBP4.974 per ordinary share.

(5) The exercise price for the share option is denominated in United States dollar per American depositary share.

(6) The exercise of the share options granted is conditional upon the fulfilment of performance targets prescribed by the Board for the relevant performance periods (2023-2025, 2024-2026 and 2025-2027), as set out in the respective grant letters. For each grant, the number of share options that may become exercisable will be determined on the date of announcement of the annal results of the Company for the final financial year of the applicable performance period (i.e. the annual results announcements for the financial years ending December 31, 2025, 2026 and 2027, respectively). Vesting will occur two business days after the relevant results announcement. Any share options in respect of which the applicable performance targets are not met will lapse accordingly.

(7) The exercise price for the share option is HKD29.200 per ordinary share.

(8) The exercise price for the share option is HKD25.500 per ordinary share.

(9) 25% of Long Term Incentive Plan Awards vesting on each of March 13, 2025, March 13, 2026, March 13, 2027 and March 13, 2028.

(10) All Long Term Incentive Plan Awards will vest in 2027, three weeks after the date of completion of the share purchase for the awards for the financial year ending December 31, 2026.

**Signature:** /s/ Su Wei-guo  
**Date:** 2026-03-16

### Remarks:

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).

** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

**Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.**